NCT04422912 · Interventional trial
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Overall registry status Recruiting
Phase 1 · Phase 2
Conditions Pemphigus Vulgaris
Delaware Valley sites
- University of Pennsylvania · Philadelphia, PA · Philadelphia County · Recruiting
First posted
Registry updated
Added to the directory